Cervicogenic headache and onabotulinumtoxinA: Where do we stand?

Becker, WJ; Chitsantikul, Prin

doi:10.1177/0333102411410086

Cited by 4 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are also in line with the hypothesis that individualized injections sites could inactivate the myofascial trigger points and improve the cervical outcomes better than the fixed sites specified in the PREEMPT protocol [ 34 ]. In addition, it seems that BoNT-A have more efficacy in migraine than in cervicogenic or tension type headache [ 6 , 35 ], where the cervical spine represents the major trigger. Moreover, the improvement of the cervical parameters in both the PT groups (i.e., PT only and BoNT-A+PT) seems to be consistent with the literature that recommends the use of manual therapy in chronic migraine for the musculoskeletal dysfunctions [ 8 , 17 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

Instrumental assessment of physiotherapy and onabolulinumtoxin-A on cervical and headache parameters in chronic migraine

et al. 2021

View full text Add to dashboard Cite

Introduction The purpose of the present study is to compare the effect of the physiotherapy to onabolulinumtoxin-A, and their combination, in relation to cervical and headache parameters in patients with chronic migraine. Methods This is an observational cohort study conducted by a headache center and a physiotherapy degree course on 30 patients with chronic migraine. The patients were distributed in three groups of treatments for three months: onabolulinumtoxin-A only, physiotherapy only, and onabolulinumtoxin-A plus physiotherapy. The patients were evaluated, before and after each treatment, using the following: the postural assessment software SAPO for the forward head posture; the CROM goniometer for the cervical range of motion; the Migraine Disability Assessment Score for headache parameters. Results After 3 months of each treatment, the scores obtained for the headache-related disability and the frequency of migraine decreased significantly for all groups, but the pain intensity scores changed significantly only in the onabolulinumtoxin-A (p = 0.01) and in the onabolulinumtoxin-A plus physiotherapy groups (p = 0.007). On the other hand, the forward head posture was reduced significantly in the physiotherapy (p = 0.002) and in the onabolulinumtoxin-A plus physiotherapy groups (p = 0.003). The cervical range of motion increased significantly in certain directions in the physiotherapy group and in the onabolulinumtoxin-A plus physiotherapy groups. Conclusions The physiotherapy improved the cervical parameters. The onabolulinumtoxin-A decreased pain intensity. As a consequence, it can be said that the combined treatment was more useful than a mono-therapy alone. From our results, it can be concluded that onabolulinumtoxin-A plus physiotherapy could be a good option in the management of chronic migraine.

show abstract

Section: Discussionmentioning

confidence: 99%

Instrumental assessment of physiotherapy and onabolulinumtoxin-A on cervical and headache parameters in chronic migraine

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This study, therefore, represents the largest series of patients treated with OBA for headaches attributed to mTBI. A single case report and several case series of patients with cervicogenic complications have demonstrated some efficacy for OBA . In addition, unusual headache types, including focal or nummular pain, have been shown to improve with OBA injections of different qualities and protocols .…”

Section: Discussionmentioning

confidence: 99%

“…A single case report and several case series of patients with cervicogenic complications have demonstrated some efficacy for OBA. [45][46][47][48][49] In addition, unusual headache types, including focal or nummular pain, 50 have been shown to improve with OBA injections of different qualities and protocols. [51][52][53] Previous studies of the utility of OBA for secondary headaches have not been of high enough quality to recommend its use.…”

Section: Discussionmentioning

confidence: 99%

Onabotulinum ToxinAfor the Treatment of Headache in Service Members With a History of Mild Traumatic Brain Injury: A Cohort Study

2015

View full text Add to dashboard Cite

show abstract

“…OnabotulinumtoxinA is therefore administered to the scalp, since migraine pain is believed to come from the meninges, as well as to the forehead, bridge of the nose, the temples, the back of the head, and neck (Figs. 1,2) [21,23]. Some studies have suggested that the optimal injection points for onabotulinumtoxinA in the treatment of chronic migraine are in the temporal region and that it should be administered >45 mm above the zygomatic arch to avoid injection into the tendon [24,25].…”

Section: Onabotulinumtoxina and Chronic Migrainementioning

confidence: 99%

“…Cervicogenic headache is associated with throbbing pain and is always triggered by mechanical causes [79]. Several studies have reported benefits for onabotulinumtoxinA treatment in headaches related to the neck [23]. In a case report of a patient with a 5-year history of cervicogenic headache following whiplash injury, a dramatic response was observed after a single BT injection despite being medically refractory to usual therapies [80].…”

Section: Onabotulinumtoxina and Cervicogenic Headachementioning

confidence: 99%

OnabotulinumtoxinA for the treatment of headache: an updated review

Talbet¹,

Elnahry²

2022

J. Integr. Neurosci.

View full text Add to dashboard Cite

Botulinum toxin (BT) is a neurotoxin produced by Clostridium botulinum, a gram-positive anaerobic bacterium. Systemic human intoxication from BT following oral ingestion results in acute and lifethreatening muscle paralysis called botulism. BT has a wide scope of therapeutic uses, including conditions associated with increased muscle tone, smooth muscle hyperactivity, salivation, sweating, and allergies, as well as for cosmetic purposes. Several commercial forms of BT are available for medical use, including Botox (onabotulinum-toxinA). Multiple studies have found evidence of an analgesic e fect of onabotulinumtoxinA and demonstrated the benefits of its use for the treatment of various chronic pain disorders. In this review, we provide an update on the use of onabotulinumtoxinA for the treatment of headache disorders.

show abstract

Cervicogenic headache and onabotulinumtoxinA: Where do we stand?

Cited by 4 publications

References 16 publications

Instrumental assessment of physiotherapy and onabolulinumtoxin-A on cervical and headache parameters in chronic migraine

Instrumental assessment of physiotherapy and onabolulinumtoxin-A on cervical and headache parameters in chronic migraine

Onabotulinum ToxinAfor the Treatment of Headache in Service Members With a History of Mild Traumatic Brain Injury: A Cohort Study

OnabotulinumtoxinA for the treatment of headache: an updated review

Contact Info

Product

Resources

About